Evidence map›Paper›PMID 34255688›Full record

ArticleJMIR medical informatics2021

Digital Medical Device Companion (MyIUS) for New Users of Intrauterine Systems: App Development Study.

Toeresin Karakoyun, Hans-Peter Podhaisky, Ann-Kathrin Frenz, Gabriele Schuhmann-Giampieri, Thais Ushikusa, Daniel Schröder, Michal Zvolanek, Agnaldo Lopes Da Silva Filho

Abstract read
In one paragraph

Article in JMIR medical informatics, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed.

  1. Review
  2. Review
  3. Article
  4. Article
  5. Digital Tools-Regulatory Considerations for Application in Clinical Trials.Therapeutic innovation & regulatory science · 2023
    Article
  6. Article
  7. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Toeresin KarakoyuneHealth and Medical Software Solutions, Bayer AG, Wuppertal, Germany.ORCID https://orcid.org/0000-0002-5638-5400
Hans-Peter PodhaiskyRegulatory Medical Device Excellence, Bayer AG, Berlin, Germany.ORCID https://orcid.org/0000-0003-3414-9252
Ann-Kathrin FrenzMedical Affairs Statistics, Bayer AG, Wuppertal, Germany.ORCID https://orcid.org/0000-0002-2315-1480
Gabriele Schuhmann-GiampieriMedical Affairs, Real World Evidence and Outcomes Data Generation, Bayer AG, Berlin, Germany.ORCID https://orcid.org/0000-0002-9037-2873
Thais UshikusaMedical Affairs, Bayer SA, Sao Paulo, Brazil.ORCID https://orcid.org/0000-0002-5789-5605
Daniel SchröderBAYOOMED Medical Software Development, BAYOONET AG, Darmstadt, Germany.ORCID https://orcid.org/0000-0001-5131-6513
Michal ZvolanekMedical Affairs, Bayer AG, Berlin, Germany.ORCID https://orcid.org/0000-0003-3154-146X
Agnaldo Lopes Da Silva FilhoDepartment of Gynecology and Obstetrics, Federal University of Minas Gerais, Belo Horizonte, Brazil.ORCID https://orcid.org/0000-0002-8486-7861

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundWomen choosing a levonorgestrel-releasing intrauterine system may experience changes in their menstrual bleeding pattern during the first months following placement.

objectiveAlthough health care professionals (HCPs) can provide counseling, no method of providing individualized information on the expected bleeding pattern or continued support is currently available for women experiencing postplacement bleeding changes. We aim to develop a mobile phone-based medical app (MyIUS) to meet this need and provide a digital companion to women after the placement of the intrauterine system.

methodsThe MyIUS app is classified as a medical device and uses an artificial intelligence-based bleeding pattern prediction algorithm to estimate a woman's future bleeding pattern in terms of intensity and regularity. We developed the app with the help of a multidisciplinary team by using a robust and high-quality design process in the context of a constantly evolving regulatory landscape. The development framework consisted of a phased approach including ideation, feasibility and concept finalization, product development, and product deployment or localization stages.

resultsThe MyIUS app was considered useful by HCPs and easy to use by women who were consulted during the development process. Following the launch of the sustainable app in selected pilot countries, performance metrics will be gathered to facilitate further technical and feature updates and enhancements. A real-world performance study will also be conducted to allow us to upgrade the app in accordance with the new European Commission Medical Device legislation and to validate the bleeding pattern prediction algorithm in a real-world setting.

conclusionsBy providing a meaningful estimation of bleeding patterns and allowing an individualized approach to counseling and discussions about contraceptive method choice, the MyIUS app offers a useful tool that may benefit both women and HCPs. Further work is needed to validate the performance of the prediction algorithm and MyIUS app in a real-world setting.

Indexed as

levonorgestrel-releasing intrauterine systemmedical devicemobile medical appmobile phone

Identifiers

PMID34255688
PMCPMC8317031

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.